BMS' Opdivo gets green light for UK early access scheme
This article was originally published in Scrip
In what appears to be only the second such decision by the UK regulator, the MHRA, Bristol-Myers Squibb's advanced melanoma product Opdivo (nivolumab) has been given the go-ahead to enter the Early Access to Medicines Scheme (EAMS), meaning it can be made available in advance of its EU approval.
You may also be interested in...
The lack of availability of coronavirus vaccines in many less well off parts of the world is an open invitation to criminals seeking to sell falsified or substandard versions. Many instances of vaccine theft and diversion have also been found.
New government funding to boost vaccine manufacturing and research into variant vaccines is being made available as part of the UK’s ambitious plans for a partnership to accelerate the availability of vaccines and other products for future pandemics.
Coronavirus Notebook: WHO’s Plan For Vaccine Manufacturing In Lower-Income Countries, UK Urged To Back IP Waiver
The UK’s independent vaccines committee has finalized its recommendations for the second phase of the COVID-19 vaccination program, and safety issues with several vaccines are still hitting the headlines.